|Bid||23.66 x 900|
|Ask||23.67 x 4000|
|Day's Range||23.61 - 23.69|
|52 Week Range||2.81 - 23.89|
|Beta (3Y Monthly)||-1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.33|
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Endocyte (ECYT) delivered earnings and revenue surprises of -6.25% and 330.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 17 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the third quarter ended Sept. 30, 2018 and provided an operational update. “177Lu-PSMA-617’s value as a potential treatment for patients with mCRPC has been reinforced in both our regulatory interactions and our entry into a merger agreement with Novartis AG, along with our longstanding interactions with patients and physicians in the prostate cancer community,” said Mike Sherman, president and CEO of Endocyte. Announced on October 18, 2018, our entry into an agreement and plan of merger with Novartis AG (Novartis), subject to the terms and conditions of which Novartis will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
Bayer's (BAYGn.DE) chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion (£48.4 billion) , have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.
Bayer's chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion, have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.
NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...
NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.
Novartis AG on Thursday said it would pay $2.1 billion for Endocyte Inc., a U.S. company developing a new treatment for prostate cancer, the Swiss pharmaceutical giant’s latest move to double down on high-value prescription drugs. Endocyte specializes in so-called radiopharmaceuticals, a new class of drug that carries radioactive substances directly to cancer cells so they can kill tumor cells at close range. Novartis agreed to pay $24 a share for the company.
All three of the major indices sold off into the close on Thursday, and the selling accelerated midday after Treasury Secretary Steven Mnuchin announced that he will not be attending a summit in Saudi Arabia.
Endocyte rallied more than 1,600 percent in the past 13 months as it advanced its prostate drug candidate -- climaxing on Thursday as Novartis splashed out $2.1 billion on a friendly buyout. The deal came at a 54 percent premium to Wednesday’s close and rewarded a group of sector specialist funds that made big bets on Endocyte, a small Indiana-based drugmaker that’s faced down concern its drug might not be ready for prime time. The biggest winner was apparently VenBio Select Advisor LLC, known for making bets across the drug discovery landscape and the largest holder with more than 7 percent of Endocyte as of the latest filing period ended June 30.
Expanding further into the increasingly competitive field of oncology, Swiss drugmaker Novartis AG (NVS) announced on Thursday morning it is buying biopharmaceutical company Endocyte Inc. (ECYT) in a deal valued at $2.1 billion. Warning! GuruFocus has detected 3 Warning Signs with NVS. According to the terms of the all-cash agreement, Novartis will pay $24 per share for the West Lafayette, Indiana-based company, a 54% premium to the stock's closing price on Oct. 17.
How do you earn an investment return that would make even the luckiest bitcoin speculator blush? Biotech company Endocyte has the answer.
On Thursday, Novartis AG agreed to pay almost 200 times that amount for the drug’s current owner, Endocyte Inc. The experimental therapy is the centerpiece of Novartis’s $2.1 billion planned takeover of U.S.-based Endocyte. It pairs tumor-killing radiation with molecules that target diseased cells, and Novartis Chief Executive Officer Vas Narasimhan says it has blockbuster potential.
The deal values the developer of cancer treatments at $24 a share, a 54% premium to Endocyte's closing price on Wednesday of $15.56. Novartis will get its hands on Endocyte's promising Lu-PSMA-617, a radioligand treatment that targets prostate cancer by attaching radioactive Lutetium to cancerous cells. "The proposed acquisition of Endocyte builds on our growing capability in radio-pharmaceuticals, which is expected to be an increasingly important treatment option for patients and a key growth driver for our business," said Novartis Oncology CEO Liz Barrett in a statement.
Endocyte, Inc. (NASDAQ: ECYT ) on Thursday announced its $2.1-billion cash sale to Novartis AG (NYSE: NVS ). The deal values Endocyte at $24 per share, representing a 54-percent premium from the firm’s ...
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Anixa Biosciences Inc (NASDAQ: ANIX ) Down In The Dumps ...
A big deal for drug maker Novartis. It’s buying cancer pharma company Endocyte for $2.1B. Yahoo Finance’s Alexis Christoforous, Scott Gamm and Julia La Roche have more.